stephen lyle
Private Equity Investor at Stage 1 Ventures LLC
Profile
Dr. Lyle is the Director of KEW Group’s Molecular Diagnostics Lab and is the former Lab Director of Predictive Biosciences, and former Medical Director of Catalyst Oncology, Inc. He has served as a consultant for a number of biotech companies including Pavonis/Beauty Medicines, Switch Biotech AG, Andorra, Inc./Living Proof, Dyax Corp., Diagnocure, Inc., Arresto Biosciences, Merrimack Pharmaceuticals and Bioserve.
Dr. Lyle holds an appointment as Associate Professor of Cancer Biology and Pathology, UMass Medical School and is the Co-Director of the UMass Cancer Center Tissue Bank.
He has held NIH and private foundation grants to study adult stem cell biology, cancer stem cells and skin biology.
He has received a multiple awards, grants and fellowships from The National Institutes of Health, William Keck Foundation, The Ellison Foundation, Society of Investigative Dermatology, Dermatology Foundation, Burroughs Wellcome Trust, and The March of Dimes.
He is a member of The American Association for Cancer Research, The Society of Investigative Dermatology and is a Fellow of the College of American Pathologists.
He is an author on over 75 research publications, book chapters and reviews
Dr. Lyle is a graduate of The Pritzker School of Medicine/University of Chicago where he completed his M.D.
and Ph.D.
in Biochemistry and Molecular Biology.
He also graduated with honors from the University of Chicago in the combined B.A.
/ M.S.
program in Biochemistry.
stephen lyle active positions
| Companies | Position | Start |
|---|---|---|
Stage 1 Ventures LLC
 Stage 1 Ventures LLC Investment ManagersFinance Stage 1 Ventures LLC (Stage 1 Ventures) is a venture capital firm founded in 2006 by David William Baum. The firm is headquartered in Miami, Florida. | Private Equity Investor | - |
Kew, Inc.
 Kew, Inc. Medical/Nursing ServicesHealth Services Kew, Inc. provides oncology services. It provides multiple services to oncologists to assist in treatment decisions for cancer patients and offers genomic testing for patient tumor samples and genomic information important to diagnostic and treatment decisions that assist physicians and are detailed in cancer-specific Therapeutic Pathways. The company was founded by Richard Bohmer, Viren Mehta, Clayton Matt Christensen, Jeffrey Elton, Mason Freeman, John P. Glaser, H. Robert Horvitz, Bruce Johnson, Kathy Behrens Wilsey and Raju S. Kucherlapat in 2009 and is headquartered in Cambridge, MA. | Private Equity Investor | - |
| UMass Chan Medical School | Private Equity Investor | - |
Former positions of stephen lyle
| Companies | Position | End |
|---|---|---|
| Catalyst Oncology, Inc. | Private Equity Investor | - |
Predictive Biosciences, Inc.
 Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Private Equity Investor | - |
Training of stephen lyle
| Pritzker School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Stage 1 Ventures LLC
Stage 1 Ventures LLC Investment ManagersFinance Stage 1 Ventures LLC (Stage 1 Ventures) is a venture capital firm founded in 2006 by David William Baum. The firm is headquartered in Miami, Florida. | Finance |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Health Services |
Kew, Inc.
Kew, Inc. Medical/Nursing ServicesHealth Services Kew, Inc. provides oncology services. It provides multiple services to oncologists to assist in treatment decisions for cancer patients and offers genomic testing for patient tumor samples and genomic information important to diagnostic and treatment decisions that assist physicians and are detailed in cancer-specific Therapeutic Pathways. The company was founded by Richard Bohmer, Viren Mehta, Clayton Matt Christensen, Jeffrey Elton, Mason Freeman, John P. Glaser, H. Robert Horvitz, Bruce Johnson, Kathy Behrens Wilsey and Raju S. Kucherlapat in 2009 and is headquartered in Cambridge, MA. | Health Services |
| Catalyst Oncology, Inc. | Health Services |
- Stock Market
- Insiders
- stephen lyle
